Phase II Trial of Sorafenib (Nexavar) in Patients With Advanced Thyroid Cancer

NCT00654238 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

59

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Differentiated Thyroid Cancer
Metastatic Poorly Differentiated Thyroid Cancer
Metastatic Anaplastic Thyroid Cancer
Metastatic Medullary Thyroid Cancer

Interventions

DRUG: sorafenib

Sponsor

University of Pennsylvania